Recently a complement C3 inhibitor and a C5 inhibitor have been FDA approved for the treatment of geographic atrophy but have not demonstrated improvement in visual function, have produced some serious adverse events and barely reduce the growth rate of the geographic atrophy (22). This evidence concerns the gene C5 and atrophic macular degeneration.